Formulation and Evaluation of Novel Drug Delivery System of Passiflora Incarnata for Antianxiety Activity

At the present time, anxiety is among the most common mental illnesses. The main causes of anxiety are psychological stress, traumatic damage, stress brought on by various medical conditions, genetic factors, drug and alcohol abuse, and other mental health conditions. Anxiety can have a major impact on a person's day-to-day functioning. It can lead to decreased coordination, an irregular sleep schedule, difficulty concentrating at work, appetite loss, and an elevated risk of suicide, particularly in those who are depressed. Benzodiazepines (diazepam, lorazepam, oxazepam), azapirones (Busipirone, Gepirone), antidepressants such as SSRIs (Paeoxetine, Fluoxentine), and SNRIs (Duloxetine, Venlafaxine) are being used to treat anxiety. Anxiety disorders can also be treated with other medications, such as tricyclic antidepressants (Clomipramine, Imipramine), antihistaminics (Hydroxyzine), and MOIs (Tranylcypromine). Compared to pricey synthetic medications, herbs can be a highly effective preventive medicine and be of significant value when included in a health programme. Numerous allopathic formulations are employed, such as clonazepam, lorazepam, alprazolam, and diazepam, however they have major adverse effects such diarrhoea, fast heartbeat, vertigo, nausea, and psychosis. Benzodiazepines and antidepressants are frequently used in modern allopathic treatment to treat anxiety disorders. However, there are side effects including vertigo and depression linked to these medications. Studies indicate that extract from Passiflora Incarnata may reduce anxiety and associated diseases via modulating the GABA A receptor, as evidenced by the plant's aerial part's antianxiety activity. It has been noted that Passiflora Incarnata has better therapeutic activity and is safer and more effective. According to recent studies, Passiflora Incarnata has good sedative and anxiolytic effects on anxiety. Anxiety, sadness, and related mental disorders may arise as a result of elevated oxidation and inflammation, according to recent studies that suggests these conditions may impact specific brain regions. Our study leads us to conclude that the combination of an anxiolytic medication with an antioxidant and an anti-inflammatory agent may result in greater anxiolytic activity and synergistic activity.